Cost Effectiveness of New Diagnostic Tools for Cutaneous
                Leishmaniasis in Afghanistan by Aerts, Céline et al.
Vol.:(0123456789)
Applied Health Economics and Health Policy 
https://doi.org/10.1007/s40258-018-0449-8
ORIGINAL RESEARCH ARTICLE
Cost Effectiveness of New Diagnostic Tools for Cutaneous 
Leishmaniasis in Afghanistan
Céline Aerts1 · Martijn Vink2 · Sayed Jalal Pashtoon3 · Sami Nahzat4 · Albert Picado5 · Israel Cruz5 · Elisa Sicuri1,6
 
© The Author(s) 2018
Abstract
Background and Objectives Cutaneous leishmaniasis is responsible for chronic and disfiguring skin lesions resulting in 
morbidity and social stigma. The gold standard to diagnose cutaneous leishmaniasis is microscopy but has a variable sen-
sitivity and requires trained personnel. Using four scenarios, the objective of this study is to compare the cost effectiveness 
of microscopy with two new tools: Loopamp™ Leishmania Detection Kit (LAMP) and CL Detect™ Rapid Test (RDT).
Methods Data related to the cost and accuracy of these tools were collected at the clinic of the National Malaria and Leish-
maniasis Control Program in Kabul, Afghanistan. The effectiveness estimates were measured based on the tools’ performance 
but also indirectly, using the disability-adjusted life years. A decision tree was designed in TreeAge Healthcare Pro 2016, 
combined with a Markov model representing the natural history of cutaneous leishmaniasis. In addition to a deterministic 
analysis, univariate sensitivity and probabilistic analyses were performed to test the robustness of the results.
Results If the tools are compared at the National Malaria and Leishmaniasis Control Program level in a period of low inci-
dence, microscopy remains the preferred option. LAMP becomes more appropriate during cutaneous leishmaniasis seasons 
or outbreaks when its capacity to process several tests (e.g. up to 48) at a time can be maximised. RDT has a cost similar to 
microscopy when used at the reference clinic but as it is relatively easy to use, it could be implemented at the peripheral level, 
which would become cheaper than employing microscopy at the reference clinic. Moreover, combining RDT with microscopy 
or LAMP at the reference clinic for the negative suspects is economically more interesting than directly performing LAMP 
or microscopy respectively on all cutaneous leishmaniasis suspects at the reference clinic.
Conclusions When taking advantage of their respective strengths, LAMP and RDT can prove to be cost-effective alternatives 
to using microscopy alone at the reference clinic.
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Key Points for Decision Makers 
If the diagnoses are to be made at a reference clinic in a 
period of low incidence, it is not worth replacing micros-
copy with the novel tools.
The Loopamp™ Leishmania Detection Kit (LAMP) 
is particularly relevant during cutaneous leishmaniasis 
seasons or outbreaks when its capacity to process several 
tests at a time is used (i.e. minimum of 35 tests).
The characteristics of the CL Detect™ Rapid Test (RDT) 
make its implementation feasible in peripheral health 
centers. A primary screening with RDT in peripheral 
centers followed by LAMP or microscopy at the refer-
ence clinic for the negative suspects is more cost effec-
tive than screening all suspects at the reference clinic 
directly with LAMP or microscopy respectively. This is 
conditional on the fact that follow-up treatments are car-
ried out in peripheral centers as well.
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1 Introduction
The leishmaniases are a group of infections caused by proto-
zoan parasites of the Leishmania genus that are transmitted 
to humans through the bites of infected female phlebotomine 
sandflies. There are three main forms of leishmaniasis: vis-
ceral, mucocutaneous and cutaneous. Cutaneous leishma-
niasis (CL) is the most common form of the disease and 
produces lesions on exposed parts of the body [1]. Although 
not fatal, it is responsible for chronic and disfiguring skin 
lesions resulting in high morbidity and social stigma [2, 3]. 
More than 100,000 new cases of CL are reported annually to 
the World Health Organization in the Eastern Mediterranean 
Region. Nevertheless, the incidence is estimated to be three 
to five times higher as most cases are either undiagnosed or 
not reported to health authorities [4].
Afghanistan is one of the countries with the highest prev-
alence of CL, caused by Leishmania major and Leishmania 
tropica [5]. The latter is the most prevalent and is related to 
anthroponotic urban transmission. It can evolve into cutane-
ous leishmaniasis recidivans (CLR) characterised by papular 
lesions appearing around the scar of a healed lesion months 
to years after a clinical cure, which may last for many years 
[4, 6]. Although efforts have been made to rebuild the 
Afghan healthcare system after the fall of the Taliban regime 
in 2001, the country is struggling with insecurity, corrup-
tion, low-quality health services and accessibility to health 
services [6]. Accordingly, cost-effective solutions to tackle 
public health priorities are needed, and as for leishmaniasis 
specifically, significant improvements in the diagnostic and 
treatment strategies are necessary.
The main diagnostic tools for CL are microscopy and pol-
ymerase chain reaction (PCR) but both have their respective 
drawbacks. Microscopy, considered as the mainstay diag-
nosis method, requires trained personnel and has a low and 
variable sensitivity, which, in many cases, leads clinicians 
to neglect its use and reach a diagnosis based on clinical 
judgements [7]. However, the broad variety of CL manifesta-
tions complicates its clinical diagnosis and its identification 
among other infectious and non-infectious diseases such as 
psoriasis, blastomycosis, chromoblastomycosis, sarcoido-
sis, and cutaneous tuberculosis in the Eastern Mediterra-
nean Region. Additionally, in long-lasting lesions, the lesion 
may expand but the parasite load decreases over time, which 
makes its detection more difficult. In such cases, molecu-
lar diagnosis (i.e. PCR) has shown to be far more sensitive 
than microscopy [8, 9]. Nevertheless, this tool requires well-
equipped laboratory facilities and experienced laboratory 
staff, as well as sufficient financial resources, which prevents 
its use outside well-equipped laboratories [10].
Thus, there is a need to move towards user-friendly, cost-
effective and field-amenable diagnostic options. This need is 
further heightened by the current treatment options for CL. 
Treatment regimens are not standardised; the first-line treat-
ment in Afghanistan is based on injectable pentavalent anti-
mony, which is usually intra-lesional but may require sys-
temic (intramuscular) administration in complicated cases 
such as CLR. The daily intramuscular injections impose 
significant travel costs and commuting time to the patients. 
Although effective, these injections can be toxic and cause 
serious side effects [11, 12]. Accordingly, accurate diagnosis 
will ensure that only those infected will be given treatment, 
avoiding unnecessary and unpleasant treatment, the misuse 
of available drugs and the emergence of drug resistance.
In a context such as Afghanistan where skilled health 
workers are lacking, improving technology can help increas-
ing labour productivity and the quality of CL detection. Two 
point-of-care diagnostic tools have been recently developed: 
Loopamp™ Leishmania Detection Kit (LAMP) [Eiken 
Chemical Co., Japan] and CL Detect™ Rapid Test (RDT) 
[InBios International Inc., USA] (a detailed description of 
these tools is given in the Electronic Supplementary Mate-
rial [ESM]). On the one hand, LAMP is able to perform as 
well as PCR in terms of sensitivity and specificity but the 
reagents come in a ready-to-use dry format that is stable 
at ambient temperature. The results are obtained faster and 
can be visualised directly using simple detection methods 
[13]. Additionally, LAMP can process several tests at a time, 
from 8 to 48 or more, depending on the machine. On the 
other hand, RDT is fast and easy to use, does not require 
any machine as opposed to LAMP and microscopy, and has 
a close to perfect specificity [14].
To our knowledge, there is no cost-effectiveness study 
comparing the available diagnostic tools for CL; the avail-
able cost-effectiveness studies on CL tend to focus on treat-
ment strategies instead [15–19]. To fill this gap, the objec-
tive of this study is to compare the cost effectiveness of RDT 
and LAMP with that of microscopy, using PCR as a refer-
ence [20–22]. We use four hypothetical scenarios. Scenario 
1 compares the above tools in a reference clinic, the National 
Malaria and Leishmaniasis Control Program (NMLCP), 
assuming one test is performed at a time, whereas scenario 
2 compares the same tools in the same clinic but assumes a 
high incidence of CL (e.g. winter season) where the assumed 
full capacity of the LAMP is being used (48 tests processed 
at a time). Scenario 3 attempts to capture the benefit of 
implementing RDT in remote healthcare facilities compared 
to the implementation of LAMP and microscopy in the ref-
erence clinic. In this scenario, treatment is administered 
in remote facilities, thus diminishing the associated treat-
ment costs to the patient by reducing commuting times and 
expenses. Last, scenario 4 relies on the same assumptions, 
except that negative RDT suspects are tested again at the 
NMLCP with microscopy or LAMP.
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2  Data and Methods
2.1  Study Population and Diagnosis
The new diagnostic tools were evaluated among 274 indi-
viduals presenting themselves with suggestive signs of CL 
at the leishmaniasis clinic of the NMLCP in Kabul; a depart-
ment of the Ministry of Public Health. The clinic is the CL 
reference clinic in Kabul treating 5000–7000 new CL cases 
per year. To be enrolled in the study, inclusion criteria were: 
(1) older than 2 years of age; (2) consenting to participate; 
and (3) not receiving treatment for CL at the time of enrol-
ment. Samples from participants were subject to the four 
diagnostic tests: microscopy, LAMP, RDT and PCR (see 
details in the ESM). A logistic regression was performed 
to assess whether individual-level characteristics, age and 
sex were significantly associated with being positive for 
CL (when presenting skin lesions). The recruitment period 
spanned from April to June 2016.
2.2  Cost‑Effectiveness Model Structure
We developed a decision tree designed in TreeAge Health-
care Pro 2016 (TreeAge Software, Williamstown, MA, 
USA), which was combined with a Markov model represent-
ing the natural history of CL due to L. tropica (see Figs. 1 
and 2), as all patients have shown to be infected with this 
Leishmania species. The model is based on a static cohort of 
10,000 individuals and runs for 80 annual cycles. Individu-
als enter the model at the age of 6 years: the youngest age 
observed in the study population. To follow the cohort over a 
life-long span, the individual entering the model encounters 
an annual probability of dying, which is independent of CL 
and varies across age groups and sex. The Markov model 
is composed of seven mutually exclusive health states and 
starts with “no skin lesion”, “skin lesion(s)” and “death” 
states to translate this health facility-based study into a com-
munity-based study and to capture the risk of infection in an 
endemic area. The remaining health states include the “No 
CL”, “CL”, “cure” and the “CLR” states (see Fig. 2).
Each annual cycle, the individual either stays in the same 
health state or moves to another one according to transition 
probabilities (see Table 4). If the individual is healthy and 
does not have skin lesions, he/she can: (1) remain healthy; 
(2) develop skin lesion(s); or (3) die for reasons independ-
ent of CL. If the individual presents with skin lesion(s), the 
lesions might be due to: (1) CL, which is equal to the per-
centage of confirmed CL cases observed at the health facil-
ity or (2) other diseases (i.e. “No CL”). Alternatively, the 
individual may die for unrelated reasons. Whether the CL-
positive cases are detected will not only depend on the sen-
sitivity of the tools but also on the likelihood that infected 
people seek a diagnosis. What follows after a true-positive or 
a false-negative case is best explained in Fig. A1 in the ESM.
If a patient is infected by L. tropica and develops CL, he/
she can either: (1) remain infected for another year; [4, 10] 
(2) become cured; or (3) die. If a patient is not infected with 
L. tropica (i.e. “No CL”), he/she can either: (1) stay unin-
fected for another cycle; (2) become infected and develop 
CL according to the incidence rate; (3) or die. Once the 
patient has cured from a CL infection (i.e. “Cure”), he/she 
can: (1) stay cured; (2) develop CLR (“CLR” state) [23]; 
or (3) die. Patients infected with CLR can: (1) stay infected 
with CLR for up to 10 years; [4] (2) become cured; or (3) 
die. Nonetheless, it is worth highlighting that no cases of 
CLR were recorded among the study population.
2.3  Cost Estimates
Data on costs were collected through three tailor-made ques-
tionnaires capturing both the patient and the health system 
perspective. Costs figures were initially collected in local 
currency (i.e. Afghan Afghani) and were then translated into 
US dollars using the exchange rate for the year 2016 (i.e. 
0.015). First, the ‘patient cost questionnaire’ (see question-
naire I in the ESM) was administered to a subset (n = 111) 
of the 274 individuals enrolled in the study, regardless of 
their diagnostic results. The first half of the questionnaire 
was completed on the day of the diagnosis and the remain-
ing half was completed at the end of the treatment period by 
positive patients only, with the help of a fieldworker. This 
questionnaire gathers information related to direct (i.e. trans-
portation) and indirect (i.e. wage loss during travelling and 
incapacity to work during illness period) costs associated 
with a potential CL episode. Patient costs were controlled for 
individual-level characteristics (i.e. age, sex and occupation) 
by matching cost estimates obtained from this questionnaire 
to a patient folder that collected information on individual 
characteristics such as occupation and family income. This 
led to a reduced subset of 85 individuals. Second, the ‘labo-
ratory and medical staff’ questionnaire (see questionnaire 
II in the ESM) captures cost estimates among medical staff 
running CL diagnostics. These include the time spent on 
average per diagnostic; the types of medical staff required 
and their salaries; and the equipment required to run the 
diagnostic. The market price of the kits and the cost of the 
machines/instrument (i.e. incubator/thermocycler in the 
case of LAMP) were also included. The cost of the instru-
ments was calculated over 80 years, the cohort life expec-
tancy, assuming a life span of 5 years. DNA extraction cost 
was included for LAMP. Last, an additional questionnaire 
was administered to medical staff: the ‘drug and treatment’ 
questionnaire (see questionnaire III in the ESM), which col-
lected information mainly related to costs of intra-lesional 
and intramuscular treatment. Treatment cost is based on the 
 C. Aerts et al.
generic price of  Pentostam®, which is donated by the World 
Health Organization in Afghanistan [24]. Patients pay out-
of-pocket-associated travel expenses and incur a wage loss 
from travelling and waiting to receive the daily injections. If 
treatment was intra-lesional, patients would have to receive 
3–5 injections, whereas if treatment was intramuscular, 
patients would have to receive 14–21 injections implying 
considerable travel expenses. Lastly, all cost parameters 
were discounted at 3% per annum as recommended by World 
Health Organization guidelines [25].
2.4  Effectiveness Estimates
In the economic model, the effectiveness estimates were esti-
mated directly through the sensitivity and specificity of the 
tools, as presented in Table 1, but also indirectly through an 
indicator of disease burden: the disability-adjusted life years 
(DALYs). The DALYs were estimated per annual cycle and 
because CL is not lethal these are an estimation of years 
lived with disability. To better understand and capture the 
impact of a CL episode on a patient’s quality of life, the 
standardised ‘Dermatology Life Quality Index’ (DLQI) 
questionnaire was administered to individuals enrolled in the 
study and used as an indicator of social stigmatisation [26] 
(see questionnaire IV in the ESM). Information collected 
through the DLQI informed the calculation of DALYs: 
more precisely, the percentage of CL-positive people (based 
on PCR) who reported “A little”, “A lot” or “Very much” 
embarrassment and/or social stigmatisation in question 2 
were attributed a higher disability weight of 0.067. This dis-
ability weight is coded as disfigurement level 2 in the Global 
Burden of Diseases study and is defined as follows: “has a 
visible physical deformity that causes others to stare and 
comment” [27]. The remainder of the cohort was attributed 
Fig. 1  Decision tree: comparative strategies. CL cutaneous leishmaniasis, LAMP Loopamp™ Leishmania Detection Kit, RDT CL Detect™ 
Rapid Test
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a disability weight of 0.011, which is coded as disfigurement 
level 1 and defined as “a slight, visible physical deformity 
that others notice, which causes some worry and discomfort” 
[27].
As no age weighting and discounting were taken into 
account in the DALY formulation, DALYs for CL and CLR 
are simply a weighted average of disfigurement level 1 and 2, 
which can be accumulated for up to 2 and 10 years, respec-
tively [28]. However, although no discounting was taken into 
account in the DALY formulation, a discount rate of 3% per 
annum was applied in the decision tree as DALYs have a 
bigger impact in younger ages.
2.5  Scenarios
To capture the inherent benefit of the tools, four scenarios 
were studied. Scenario 1 compared microscopy, LAMP and 
RDT at the NMCLP level, assuming that the full capacity 
of the LAMP is irrelevant such that one test at a time is 
being processed. This is a rather conservative approach but 
feasible outside the CL incidence peak (i.e. outside the win-
ter season). Scenario 2 compared the tools at the NMLCP 
level but assuming here that the capacity of the LAMP to 
process several samples at a time is used fully. To do so, the 
labour cost spent on LAMP is divided by 48, its assumed 
maximum capacity. The maximum capacity of the LAMP 
can vary and hence a sensitivity analysis was conducted 
on this parameter. Scenario 3 compared microscopy and 
LAMP at the NMLCP level but RDT at the peripheral level, 
that is, in remote health facilities. To capture the benefit of 
implementing the RDT in peripheral facilities, the asso-
ciated treatment costs to the patient were diminished by 
half, which are independent of the treatment cost per se, as 
treatment is provided by the NMLCP, but instead include 
transportation costs and wage loss as a result of commut-
ing and waiting to receive the daily injections. As halving 
the treatment-associated costs when RDT is implemented 
at peripheral levels is rather arbitrary, we conducted a sen-
sitivity analysis on this parameter to look for any potential 
threshold value(s) that would alter the order of the strate-
gies. Finally, as the sensitivity of RDT is relatively low (i.e. 
Fig. 2  Natural history of Leish-
mania tropica 
Table 1  Sensitivity and specificity of the tools using polymerase 
chain reaction as a reference
CI confidence interval, LAMP Loopamp™ Leishmania Detection Kit, 
RDT CL Detect™ Rapid Test, Se sensitivity, Sp specificity
Source: [29]
Tools Diagnostic performance 
(%)
95%CI
Microscopy Se = 78.97 73.74–84.20
Sp = 77.27 57.49–97.06
RDT Se = 66.27 60.23–72.31
Sp = 95.45 84.48–100
LAMP Se = 89.68 85.73–93.64
Sp = 63.64 41.26–86.01
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a high proportion of false negatives), a fourth scenario was 
studied in which RDT is implemented at the peripheral level 
but negative patients are sent to the NMLCP to be tested 
again with microscopy or LAMP. In scenario 4 (and as in 
scenario 3), we assumed that treatment would be adminis-
tered at the peripheral level.
2.6  Data Analysis
2.6.1  Measurement of Cost Effectiveness
An intervention is judged cost effective if the incremental 
cost-effectiveness ratio (ICER) between two competing strat-
egies is below the country’s gross domestic product per cap-
ita (US$561) [30]. If the incremental effectiveness between 
strategies is close to 0, the net monetary benefit (NMB) can 
also be used for comparing strategies, NMB = threshold* 
effectiveness—cost, where the weight is put on costs. The 
strategy with the highest NMB is the one preferred—that is, 
often the one reporting the lowest cost.
2.6.2  Model Estimate and Sensitivity Analysis
The model was estimated by applying deterministic and 
probabilistic analyses. A deterministic analysis was per-
formed using the mean or median value for each parameter, 
depending on distribution skewness. Univariate sensitivity 
was applied to scenario 1 by varying the mean or the median 
values of all parameters by both − 50% and + 50% or to the 
minimum or maximum feasible values (i.e. 0 or 1 if param-
eters are probabilities). For the same scenario, threshold 
analyses were carried out on selected parameters for which 
a change (i.e. up to ± 50%) affects the chosen strategy in 
terms of their respective costs. Probabilistic analysis was 
performed through Monte Carlo simulations; the number of 
iterations needed to produce stable results was based on the 
graphical representation of the average of the cumulative 
NMB. Different probabilistic distributions were assigned to 
parameters following indications from the literature and are 
listed in Table 4 [31]. To account for uncertainty among 
individual-level cost data, we regressed the logarithm of the 
cost of being diagnosed on individual-level characteristics: 
age, sex and occupation. Occupation was divided into four 
categories: (1) no earnings: “students” and “jobless”; (2) 
unsecured jobs: “farmers” and “housekeepers”; (3) secured 
jobs: “army officer”, “government official”; and last (4) 
unknown occupations. Cholesky decomposition among 
the parameters was performed so that the variance of each 
parameters and the variability within the parameters (covari-
ance) is kept constant through a multi-normal distribution.
For the sensitivity and specificity of the tools, the dif-
ference between the upper and lower limit from the 95% 
confidence interval, based on a t Student distribution, was 
used to calculate the standard deviations. If the difference 
between the upper and lower limit was too wide to yield 
positive alpha and beta values, it was reduced until positive 
parameters were reached. For variables obtained from the 
literature or at the health facility level, a standard deviation 
of 20% was chosen. [32] Results of the probabilistic analyses 
were graphically presented through the cost-effectiveness 
plane and acceptability curves. The cost-effectiveness plane 
plots all Monte Carlo simulations for the two best strate-
gies, with respect to the incremental cost and effectiveness. 
Acceptability curves are generated using the NMB and show 
Table 2  Deterministic results
c.f. 1 refer to scenario 1, DALYs disability-adjusted life years, ICER incremental cost-effectiveness ratio, LAMP Loopamp™ Leishmania Detec-
tion Kit, NMB net monetary benefit, RDT CL Detect™ Rapid Test
Scenarios Strategies Average per person ICER Outcome NMB
Cost (2016 US$) DALYs US$ per DALY 
averted
1 Microscopy 53.79 0.0486 – Undominated − 81.03
RDT 53.91 0.049 – Dominated − 81.38
LAMP 60.18 0.0482 18614.89 Undominated − 87.23
2 Microscopy c.f. 1 c.f. 1 – Dominated c.f. 1
RDT c.f. 1 c.f. 1 – c.f. 1 c.f. 1
LAMP (full capacity) 53.73 c.f. 1 – Undominated − 80.79
3 Microscopy c.f. 1 c.f. 1 18325.54 c.f. 1 c.f. 1
RDT (peripheral) 46.32 c.f. 1 – Undominated − 73.79
LAMP c.f. 1 c.f. 1 18457.92 c.f. 1 c.f. 1
4 Microscopy c.f. 1 c.f. 1 586.24 c.f. 1 c.f. 1
RDT (peripheral) + microscopy 52.27 0.0511 – Undominated − 80.96
LAMP c.f. 1 c.f. 1 2699.6 c.f. 1 c.f. 1
RDT (peripheral) + LAMP 54.59 0.051 – Dominated − 83.2
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Fig. 3  Cost-effectiveness graph 
with willingness-to-pay (WTP) 
line. DALYs disability-adjusted 
life-years, LAMP Loopamp™ 
Leishmania Detection Kit, RDT 
CL Detect™ Rapid Test
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the probability of the tools to be cost effective according to 
different willingness-to-pay (WTP) values.
3  Results
From the logistic regression, it became clear that CL positiv-
ity was not significantly correlated with age and sex (refer to 
Table A1 in the ESM). Hence, the analyses were not strati-
fied across these two demographic variables.
3.1  Cost
The predicted mean cost incurred by patients to be tested 
reaches US$1—controlling for individual-level character-
istics—and include transportation costs and indirect costs 
related to wage lost during the clinic visits and the ill-
ness period. The results of the regression analyses as well 
as tests of linear assumptions are presented in Table A2 
and Fig. A2 of the ESM. While age and sex are not sig-
nificantly associated with patients’ costs, occupation types 
are: people with low social security jobs (e.g. house keep-
ers and farmers) experience a 99% cost increase per CL 
episode when compared with the reference group: people 
without any earnings (students and jobless). In contrast, 
occupations with more social security (e.g. retail work-
ers, tailors) experience a cost increase of 53% per episode 
compared with people without earnings. Cost of treat-
ment, borne by the health system, is higher for intramus-
cular treatment than for intra-lesional treatment, US$41 
vs. US$13, but 80% of the patients are treated with the 
latter. Travel expenses for the patients are also higher for 
intramuscular treatment than for intra-lesional treatment, 
US$18 vs. US$4. Microscopy and RDT have identical 
labour costs, which approximates to US$14 per person 
tested. LAMP is slightly more costly with approximately 
$US20 per person tested; however, this is using a con-
servative approach where one test is processed at a time.
3.2  Disability‑Adjusted Life‑Years
Based on the DLQI questionnaire, 60% of the cohort 
reported embarrassment and/or social stigmatisation as a 
result of CL and were attributed a higher disability weight 
of 0.067. The remaining 40% was attributed a lower dis-
ability weight of 0.011. Hence, on average, one episode of 
CL or CLR was associated with 0.0446 DALY annually, 
which could be accumulated for up to 2 years for patients 
infected with CL and 10 years for patients infected with 
CLR.
3.3  Cost Effectiveness
Results of the deterministic analyses are represented in 
Table 2 for each scenario but also graphically in Fig. 3.
Microscopy and LAMP are the two undominated strate-
gies in scenario 1: the first has the lowest associated cost 
while the latter has the highest associated effectiveness (i.e. 
fewer associated DALYs) but as the incremental effective-
ness between the two is close to 0, the ICER tends to infinity. 
Looking at the NMB, it is almost identical for microscopy 
Fig. 3  (continued)
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and RDT but lower for LAMP. In scenario 2, when the 
assumed full capacity of the LAMP (48 tests at once) is 
used, LAMP has the lowest cost and the highest effective-
ness: it dominates microscopy and RDT with the highest 
NMB. The sensitivity analysis on the capacity of the LAMP 
to process several tests at once has shown that: for LAMP to 
be the cheapest option, 35 tests should be processed at once 
and for LAMP to have the greater NMB, 17 tests should be 
processed at once. In scenario 3, RDT has the lowest asso-
ciated cost and the highest NMB. In other words, if imple-
mented in peripheral health centers, RDT is preferred over 
microscopy and LAMP used in the reference center. The 
assumption behind scenario 3 is that if RDT is implemented 
in remote facilities, the ensuing treatment regimens will be 
administered in the remote facilities, thereby decreasing the 
treatment-related costs to the patient. Sensitivity analyses 
of the cost of treatment, both intra-lesional and intramus-
cular, are presented in Fig. A3 of the ESM and shows that a 
decrease of at least 5% in the intramuscular treatment cost 
for patients when RDT is chosen over microscopy or LAMP. 
When it comes to scenario 4, sending the RDT negatives to 
the reference clinic to be tested with microscopy or LAMP is 
naturally more costly than using RDT alone but cheaper than 
using direct microscopy or LAMP at the NMLCP on all CL 
suspects. RDT followed by microscopy is cheaper and leads 
to higher NMB than RDT followed by LAMP.
Figure 3 provides a visual representation of the results 
where undominated strategies are connected by a line (which 
does not show in scenario 2 as LAMP dominates both RDT 
and microscopy). The gradient of this line is the ICER: the 
steeper the line, the bigger the ICER. A strategy should be 
chosen if positioned on the ICER line and crossing the WTP 
Fig. 4  Tornado diagram. Parameter categories are grouped by color: 
dark blue represents costs borne by the health system; light blue 
represents costs borne by the suspects/patients with cutaneous leish-
maniasis (CL); red represents transition rates; and green represents 
patient/clinician behaviours. The values in the parentheses stand for 
the lower and higher range over which the parameter was varied. The 
vertical line represents the expected value of the microscopy cost. A 
segmented bar indicates a change in the cost threshold: CL Detect™ 
Rapid Test becomes cheaper than microscopy. CLR cutaneous leish-
maniasis recidivans, EV, Prob probability
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slope. Accordingly, microscopy should be chosen in sce-
nario 1, LAMP in scenario 2, RDT in scenario 3 and RDT 
followed by microscopy in scenario 4.
3.4  Sensitivity Analysis
The one-way sensitivity analysis on the expected value of the 
cost of microscopy vs. RDT and LAMP (with the assump-
tion of scenario 1) is illustrated by the tornado diagram in 
Fig. 4. To start with transition rate parameters, an increase in 
the prevalence of skin lesions within the population signifi-
cantly increases the expected cost of the tools. If the prob-
ability of the skin lesions being due to CL (“Prob being CL 
given symptoms”) decreases below 78%, the expected cost 
of RDT becomes a slightly lower than microscopy (see Fig. 
A4 in the ESM). The same applies to the incidence rate of 
CLR. On the contrary, the greater the annual curing rate the 
lower the expected cost of the tools and vice versa (i.e. prob-
ability of staying with CLR for another year). When lower-
ing the probability of intra-lesional treatment from 80% to 
below 70%, RDT becomes cheaper than microscopy (see 
Fig. A4 in the ESM). The same applies to the probability of 
treatment efficacy or self-healing: if the former is lower than 
45% or the latter higher than 62%, RDT becomes the cheap-
est option (see Figs A6 and A7 in the ESM). As with cost 
parameters, it is obvious that any increase in one of these 
will result in higher expected costs of the tools. Only one 
cost parameter can affect the order of the tools when judging 
on their respective expected costs: the cost of intra-lesional 
treatment. If increasing above $US18 per treatment regimen, 
RDT becomes less costly than microscopy. Finally, as the 
probability of being treated and the adherence to treatment 
increase, the cost of the tools increases.
In the probabilistic analysis, about 1000 random iterations 
of the cost-effectiveness model were required to achieve sta-
ble results. Compared with the deterministic results, both 
the mean cost and mean effectiveness parameters have 
increased. The mean ICER in most of the scenarios is now 
tending towards infinity because for many simulations its 
denominator, the difference in DALYs, is close to zero (see 
Table 3).
Monte Carlo simulations are represented through the 
cost-effective plane in Fig. 5 and the cost-effectiveness 
acceptability curves (CEACs) in Fig. 6, in which the former 
is generated using the incremental cost and effectiveness 
and the latter using the NMB. The cost-effectiveness plane 
compares both the incremental cost and effectiveness of the 
undominated, or the two best strategies for each scenario. In 
scenario 1, almost all of the simulations are located above 
the WTP threshold, suggesting than LAMP is not preferred 
Table 3  Monte Carlo simulation results
c.f. 1 refer to scenario 1, CI confidence interval, DALYs disability-adjusted life-years, Dom. dominated, LAMP Loopamp™ Leishmania Detec-
tion Kit, RDT CL Detect™ Rapid Test, Undom. undominated
Scenarios Strategies Average per person





Cost (2016 US$) DALYs US$ per 
DALY 
averted
1 Microscopy 56.67 [54.48–58.86] 0.0513 [0.0493–0.0533] – – – Undom.
RDT 56.75 [54.55–58.94] 0.0517 [0.0497–0.0537] 0.081 0.0004 – Dom.
LAMP 62.86 [60.53–65.18] 0.051 [0.049–0.053] 6.19 − 0.0003 ∞ Undom.
2 Microscopy c.f. 1 c.f. 1 0.1286 0.0003 – Dom.
RDT c.f. 1 c.f. 1 0.21 0.0007 – Dom.
LAMP (full capacity) 56.54 [54.35–58.73] 0.051 [0.049–0.053] – – – Undom.
3 Microscopy c.f. 1 c.f. 1 8.143 − 0.0004 6924.40 Undom.
RDT (peripheral) 48.53 [46.67–50.38] 0.0517 [0.0497–0.0537] – – – Undom.
LAMP c.f. 1 c.f. 1 14.33 − 0.0007 19797.76 Undom.
4 Microscopy c.f. 1 c.f. 1 2.20 − 0.003 ∞ Undom.
RDT (peripheral) + micros-
copy
54.46 [52.51–56.42] 0.0539 [0.0519–0.0559] – – – Undom.
RDT (peripheral) + LAMP 56.74 [54.73–58.76] 0.0538 [0.0518–0.0558] 2.29 − 0.0001 – Dom.
LAMP c.f. 1 c.f. 1 8.389 − 0.0029 ∞ Undom.
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Fig. 5  Cost-effectiveness 
plane. The circle represents the 
95% ellipse (the 95% credible 
interval); the willingness-to-pay 
(WTP) line represents the WTP 
threshold that is equal to the 
one time gross domestic product 
per capita. DALYs disability-
adjusted life-years, LAMP Loo-
pamp™ Leishmania Detection 
Kit, RDT CL Detect™ Rapid 
Test
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over microscopy. In scenario 2, LAMP becomes more com-
petitive: about half of the simulations are located on or 
below the WTP threshold. The cost-effectiveness plane in 
scenario 3 suggests that RDT is significantly preferred over 
LAMP with nearly all simulations above the WTP threshold. 
Last, in scenario 4, most of the simulations are located above 
or on the WTP threshold: it appears more cost effective to 
first use RDT in the peripheral centers and perform micros-
copy on the negative patients at the reference clinic than 
directly performing LAMP (or microscopy) on all suspects 
at the reference clinic. However, as shown by the credible 
interval, the uncertainty regarding the cost effectiveness of 
this combined strategy is large.
With respect to the CEACs, as the effectiveness is close to 
0, different WTP values have little impact on modifying the 
probability of the tools to be cost effective and this further 
implies that for the tools to offer higher NMB, their respec-
tive costs must be reduced. In Scenario 1, where all tools 
are compared at the NMLCP level, RDT has a higher prob-
ability of being cost effective up to a WTP of a US$1000 per 
DALY averted, which at first seems to contradict the finding 
in Table 3 that RDT is dominated. However, because the 
CEAC is based on the NMB of each option, it is possible 
for an option to have a higher net benefit without dominat-
ing another option [33]. The probability of RDT to be cost 
effective is even greater when employed at the peripheral 
level (i.e. scenario 3): regardless of the WTP value it has 
a 95% probability to be cost effective. In scenario 2, when 
the LAMP capacity is maximised, the latter becomes more 
likely to be cost effective than RDT (at the reference clinic) 
above a WTP threshold of around US$400 per DALY 
averted. In scenario 4, RDT performed at the peripheral level 
followed by microcopy is the strategy that is most likely to 
be cost effective irrespective of the WTP value (Table 4).
4  Discussion
This article discusses four hypothetical scenarios for micros-
copy, RDT and LAMP. That is, (1) the tools are implemented 
at the referral clinic (NMLCP), assuming the conservative 
approach that one test is performed at a time with LAMP; 
(2) the tools are used at the NMLCP but assuming the full 
capacity of the LAMP is reached (e.g. 48 tests processed 
at once); (3) microscopy and LAMP are implemented as 
in scenario 1 but RDT is implemented at peripheral levels, 
which translates into lower associated treatment costs to the 
patients; and (4) the tools are implemented as in scenario 
3, except that the CL suspects tested negative with RDT 
are sent to the reference clinic to be tested a second time 
with either microscopy or LAMP. In this last scenario, we 
assumed (as in scenario 3) that treatment is administered 
at the peripheral level. Such scenarios have been designed 
to capture the inherent benefits of the tools: the capacity of 
LAMP to process multiple samples at a time and the low 
level of expertise required for RDT, making its use possible 
in centers with no or low diagnostic capacities. However, its 
variable sensitivity may require a combined strategy with 
microscopy or LAMP, as illustrated in scenario 4.
In scenario 1, LAMP has a slightly higher effectiveness 
(i.e. lower associated DALYs) but the cost increase in using 
this tool compared with microscopy is around US$6 per per-
son tested. This higher cost implies lower NMB and would 
point to the use of microscopy as demonstrated by the Monte 
Fig. 5  (continued)
Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis
Fig. 6  Cost-effectiveness 
acceptability curves. The y-axis 
represents the probability of the 
tools being cost effective while 
the x-axis represents differ-
ent willingness-to-pay values. 
LAMP Loopamp™ Leishma-
nia Detection Kit, RDT CL 
Detect™ Rapid Test
 C. Aerts et al.
Carlo simulations. RDT has a very similar cost and effective-
ness to microscopy, with crossing CEACs. In scenario 2, 
when dividing the labour cost on LAMP by 48, its associated 
cost per person tested becomes slightly cheaper than that 
of RDT and microscopy. This scenario is plausible during 
the peak of the CL season or during an outbreak [34]. It 
also makes sense if LAMP is used simultaneously for other 
diseases than CL (e.g. malaria and/or tuberculosis). In such 
cases, LAMP potentially becomes a cost-effective solution 
but the uncertainty regarding the cost effectiveness of the 
latter vs. microscopy is significant, as demonstrated by the 
cost-effectiveness plane in Fig. 5.
In scenario 3, the associated treatment costs incurred 
by the patients, which exclusively include travel costs and 
wage losses associated with commuting and waiting times 
(as diagnosis and treatment is provided free of charge), were 
halved. The sensitivity analysis on this parameter shows that 
even if decreased by just 5%, RDT becomes cheaper than 
any other strategy. We believe this is very likely to hap-
pen if the tool is implemented outside the reference clinic. 
However, one potential factor to consider if implementing 
the RDT in remote facilities is awareness-raising costs. As 
highlighted by the Ministry of Health, although the popula-
tion may be aware that diagnostic and treatment options are 
provided in remote facilities, there is a general tendency to 
go to the reference clinic (NMLCP) even if it implies hours 
or days of travelling. Another feature to consider is the pro-
portion of false negatives among CL individuals tested with 
RDT (i.e. sensitivity of 66.75%).
This is considered in scenario 4, where RDT negative 
suspects (i.e. false positive and true negative) are tested at 
the reference clinic with LAMP or microscopy. RDT fol-
lowed by LAMP is slightly more costly than RDT followed 
by microscopy and the difference in effectiveness between 
the two is negligible. This being said, it remains preferable 
to perform a primary screening of CL suspects remotely 
with RDT followed by microscopy or LAMP for the nega-
tive suspects, rather than testing all suspects directly with 
microscopy or LAMP (respectively) at the NMLCP. This 
is indeed illustrated by the CEACs in scenario 4: RDT fol-
lowed by microscopy is on average 45–50% more likely to 
be cost effective than microscopy alone.
To conclude, the novel tools are promising and have their 
respective advantages. On the one hand, LAMP may be par-
ticularly relevant in a reference clinic during high endemic 
periods. Furthermore, in a context where laboratory exper-
tise is lacking because of political instability and uncom-
petitive salaries, improving technology can significantly 
boost labour productivity. On the other hand, RDT may be 
particularly suitable in parts of the country where there is 
no/low diagnostic capacities. Such usage of RDT could be 
combined with additional testing at the reference clinic using 
other strategies with higher sensitivity. Nevertheless, even 
though this study attempts to capture the particularity of the 
tools with four different scenarios, one must keep in mind 
that estimates were collected from a single site, the NMLCP, 
which may not be representative of the whole country and 
which further implies that results may not be generalisable at 
the national level. Additionally, the results of this study are 
challenged by a very small incremental effectiveness across 
tools, questioning the use of DALYs when representing the 
burden associated with a disease such as CL. DALYs esti-
mates based on the Global Burden of Diseases report may 
not capture the full burden, such as social stigmatisation 
and emotional burden that may be particularly important for 
women of young ages, and would suggest that, perhaps, the 
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burden of CL should be measured in a more qualitative way, 
as attempted with the DLQI questionnaire.
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